(24/7 MARKET NEWS) – Timber Pharmaceuticals, Inc. (NASDAQ: TMBR) stated, this morning, that the U.S. Food and Drug Administration (FDA) granted a dermal carcinogenicity (CARC) waiver for TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG delivery system, based on results of a 39-week repeat dose dermal toxicity study.
Timber Pharmaceuticals is trading at $1.98, up $0.49 (+32.88%), on 17.20K premarket shares traded.
Its 52-week range is $1.20 to $17.485. This gapped up over its recent resistance points and, if its trading volume increases, its setup is favorable to challenge its April and March highs.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
